

# Practical Research for Innovative Cancer Control System Diagram

Program Supervisor

Dr. HOTTA Tomomitsu

Practical Research for Innovative Cancer Control (MHLW)

Practical Research for Innovative Cancer Control Management Office (PRIMO)



- Area1
- Area2
- Area3
- Area4
- Area5
- Area6

Program Officers	Research topic	Representative project themes
Dr. NAKAGAMA Hitoshi Dr. YONEDA Yoshihiro	Elucidating the etiology of cancer	<ul style="list-style-type: none"> <li>● Elucidating various causal factors that induce cancer</li> <li>● Elucidating the characteristics of cancer cells and tissues involved in metastasis, recurrence, and drug resistance</li> <li>● Elucidating the biological characteristics of cancer by integrating advanced life science technology, such as stem cell technology (iPSCs), and technologies from other fields</li> <li>● Performing molecular research to make epochal advancements in the prevention and treatment of cancer</li> </ul>
Dr. SOBUE Tomotaka Dr. NAGATA Chisato	Investigating tools for prevention and early detection of cancer	<ul style="list-style-type: none"> <li>● Aiming stratification and individualization of cancer risks by identifying individual risks based on genetic factors, disease or infection status and lifestyle factors such as smoking, diet, exercise, and work and living environments</li> <li>● Developing risk reduction techniques tailored to cancer risks in individuals</li> <li>● Developing diagnostic techniques useful in cancer screening</li> <li>● Performing a large-scale epidemiological study of tools for prevention and early detection of cancer</li> </ul>
Dr. OHTSU Atsushi Dr. NIHIRA Shin-ichi	Developing novel drugs to address unmet medical needs	<ul style="list-style-type: none"> <li>● Screening and identifying candidates for drugs in pre-clinical studies</li> <li>● Developing safe and effective novel drugs in pre-clinical studies proceeding to clinical studies</li> <li>● Conducting investigator-initiated clinical trials for regulatory approval of new agents in patients with, for example, refractory or rare cancer</li> <li>● Conducting investigator-initiated clinical trials for regulatory approval of novel cancer therapy such as immune cell therapy and gene therapy</li> </ul>
Mr. AKABORI Makoto Dr. KAGAMI Yoshikazu	Developing novel medical technologies for patient-friendly care	<ul style="list-style-type: none"> <li>● Establishment and practical application of diagnostic technology using novel biomarkers</li> <li>● Establishment of advanced medical imaging technologies such as molecular imaging, CT, MRI, endoscopy, etc. by combining novel technologies including AI</li> <li>● Development and clinical application of novel medical technologies in radiotherapy such as IMRT, stereotactic radiotherapy, particle beam therapy, BNCT, brachytherapy, etc.</li> <li>● Development of novel medical devices in cancer diagnosis and treatment</li> </ul>
Dr. SANO Takeshi Dr. TAMURA Kazuo	Developing the new standard of cancer therapy	<ul style="list-style-type: none"> <li>● Conducting multicenter collaborative clinical research to develop standard cancer therapies designed to improve treatment efficacy and tailored to individual patients or groups of patients</li> <li>● Conducting multicenter collaborative clinical research to develop standard cancer therapies designed to improve treatment safety and patient QOL</li> <li>● Developing supportive/palliative care for cancer patients (e.g., pain management, nutrition support, and rehabilitation) and evaluation systems to assess efficacy</li> </ul>
Dr. HORIBE Keizo Dr. SAEKI Toshiaki	Developing treatments tailored to life stage and cancer characteristics	<ul style="list-style-type: none"> <li>● Clinical research on the development of standard treatments for childhood cancer and AYA generation cancer</li> <li>● Clinical research on the development of standard treatments for rare cancer</li> <li>● Clinical research on geriatric oncology</li> <li>● Clinical research on the development of standard treatments for refractory cancer</li> </ul>